https://www.who.int/news/item/14-01-2022-who-recommends-two-new-drugs-to-treat-covid-19
BARICITINIB
Januskinaasin estäjä . Suositeltu käytettäväksi kortikosteroidien kanssa.
SOTROVIMAB,
vaihtoehtoislääke casirivimab-imdevimab nimisille monoklonaalisille vasta-aineille.
WHO recommends two new drugs to treat COVID-19
WHO has recommended two new drugs for COVID-19,
providing yet more options for treating the disease. The extent to which
these medicines will save lives depends on how widely available and
affordable they will be.
The first drug, baricitinib, is
strongly recommended for patients with severe or critical COVID-19. It
is part of a class of drugs called Janus kinase (JAK) inhibitors that
suppress the overstimulation of the immune system. WHO recommends that
it is given with corticosteroids.
Baricitinib is an oral
drug, used in the treatment of rheumatoid arthritis. It provides an
alternative to other arthritis drugs called Interleukin-6 receptor
blockers, recommended by WHO in July 2021.
WHO
has also conditionally recommended the use of a monoclonal antibody
drug, sotrovimab, for treating mild or moderate COVID-19 in patients who
are at high risk of hospitalization. This includes patients who are
older, immunocompromised, having underlying conditions like diabetes,
hypertension, and obesity, and those unvaccinated.
Sotrovimab is an alternative to casirivimab-imdevimab, a monoclonal antibody cocktail recommended
by WHO in September 2021. Studies are ongoing on the effectiveness of
monoclonal antibodies against Omicron but early laboratory studies show
that sotrovimab retains its activity.
The panel of experts
developing the guidelines also looked at two other drugs for severe and
critical COVID-19: ruxolitinib and tofacitinib. Given their uncertain
effects, WHO made a conditional recommendation against their use.
Today’s recommendations, forming the eighth update of WHO’s living guidelines on therapeutics and COVID-19, are based on evidence from seven trials involving over 4,000 patients with non-severe, severe, and critical COVID-19.
WHO
is in discussions with manufacturers to secure global supply capacity
and equitable and sustainable access to the newly recommended
therapeutics. The Access to COVID-19 Tools Accelerator (ACT-A)
Therapeutics pillar has been engaging with pharmaceutical companies to
seek comprehensive access plans for low- and middle-income countries, so
that these treatments can be rapidly deployed everywhere, not just in
rich countries. The ACT-A is also looking to expand licensing scope to
make the products more affordable.
The two newly recommended drugs - baricitinib and sotrovimab - have been invited for WHO Prequalification, which assesses the quality, efficacy and safety of priority health products to increase access in lower income countries.
Inga kommentarer:
Skicka en kommentar